SGC-CBP30( SGC-CBP30 | SGC-CBP 30 | SGC-CBP-30 )

Catalog No. M17342 CAS No. 1613695-14-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

SGC-CBP30
Note

Research use only, not for human use.
Brief Description

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).
Description

SGC-CBP30 is a potent and selective inhibitor of CREBBP (CBP) and EP300; which are general transcriptional co-activators. CREBBP has also been associated with Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig?’s disease, a neurodegenerative disease with progressive degeneration of motor neurons in the brain and spinal cord, Alzheimer's disease and poly glutamine repeat diseases such as Spinal and Bulbar Muscular Atrophy and Huntington?’s disease.
In Vitro

——
In Vivo

Animal Model:Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066 Dosage:25 mg/kg Administration:Oral administration; daily; for 14 days Result:Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.
Synonyms

SGC-CBP30 | SGC-CBP 30 | SGC-CBP-30
Pathway

Others
Target

Other Targets
Recptor

CREBBP| EP300
Research Area

Cancer
Indication

——

CAS Number

1613695-14-9
Formula Weight

509.04
Molecular Formula

C28H33CIN4O3
Purity

>98% (HPLC)
Solubility

DMSO : ≥ 31 mg/mL; 60.90 mM
SMILES

Cc1noc(C)c1c1cc2nc(CCc3ccc(OC)c(Cl)c3)n(C[C@H](C)N3CCOCC3)c2cc1
Chemical Name

(S)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)propan-2-yl)morpholine

1. Structural Genomics Consortium

Calculator

molnova catalog